Neuroblastoma is a malignant neoplasm of the developing sympathetic nervous system that is notable for its phenotypic diversity. High-risk patients typically have widely disseminated disease at diagnosis and a poor survival probability, but low-risk patients frequently have localized tumors that are almost always cured with little or no chemotherapy. Our genome-wide association study (GWAS) has identified common variants within FLJ22536, BARD1, and LMO1 as significantly associated with neuroblastoma and more robustly associated with high-risk disease. Here we show that a GWAS focused on low-risk cases identified SNPs within DUSP12 at 1q23.3 (P = 2.07 x 10(-6)), DDX4 and IL31RA both at 5q11.2 (P = 2.94 x 10(-6) and 6.54 x 10(-7) respectively), and HSD17B12 at 11p11.2 (P = 4.20 x 10(-7)) as being associated with the less aggressive form of the disease. These data demonstrate the importance of robust phenotypic data in GWAS analyses and identify additional susceptibility variants for neuroblastoma.
Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci / Nicholas J., Schork; B., Nguyễn Le; Sharon J., Diskin; Mario, Capasso; Wang, Kai; Maura A., Diamond; Joseph, Glessner; Cecilia, Kim; Edward F., Attiyeh; Yael P., Mosse; Kristina, Cole; Achille, Iolascon; Devoto, Marcella; Hakon, Hakonarson; Hongzhe K., Li; John M., Maris. - In: PLOS GENETICS. - ISSN 1553-7404. - 7:3(2011), pp. e1002026-1-e1002026-9. [10.1371/journal.pgen.1002026]
Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci
DEVOTO, MARCELLA;
2011
Abstract
Neuroblastoma is a malignant neoplasm of the developing sympathetic nervous system that is notable for its phenotypic diversity. High-risk patients typically have widely disseminated disease at diagnosis and a poor survival probability, but low-risk patients frequently have localized tumors that are almost always cured with little or no chemotherapy. Our genome-wide association study (GWAS) has identified common variants within FLJ22536, BARD1, and LMO1 as significantly associated with neuroblastoma and more robustly associated with high-risk disease. Here we show that a GWAS focused on low-risk cases identified SNPs within DUSP12 at 1q23.3 (P = 2.07 x 10(-6)), DDX4 and IL31RA both at 5q11.2 (P = 2.94 x 10(-6) and 6.54 x 10(-7) respectively), and HSD17B12 at 11p11.2 (P = 4.20 x 10(-7)) as being associated with the less aggressive form of the disease. These data demonstrate the importance of robust phenotypic data in GWAS analyses and identify additional susceptibility variants for neuroblastoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
